ALGS – aligos therapeutics, inc. - common stock (US:NASDAQ)
Stock Stats
News
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer
Aligos Therapeutics (NASDAQ:ALGS) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
Here's Why Aligos Therapeutics (NASDAQ:ALGS) Must Use Its Cash Wisely [Yahoo! Finance]
Aligos Therapeutics (NASDAQ:ALGS) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Form SCHEDULE 13G/A Aligos Therapeutics, Filed by: Woodline Partners LP
Form 10-Q Aligos Therapeutics, For: Sep 30
Form 8-K Aligos Therapeutics, For: Nov 06
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.